Private company

Celera Corporation

Logo: Non-free logo, via Wikipedia3

American genetic sequencing company

Celera Corporation is a subsidiary of Quest Diagnostics which focuses on genetic sequencing and related technologies. It was founded in 1998 as a business unit of Applera, spun off into an independent company in 2008, and finally acquired by Quest Diagnostics in 2011.2 It was founded by Craig Venter.1 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

May 1998Founded1
  • HeadquartersAlameda1

Celera Corporation is a subsidiary of Quest Diagnostics which focuses on genetic sequencing and related technologies. It was founded in 1998 as a business unit of Applera, spun off into an independent company in 2008, and finally acquired by Quest Diagnostics in 2011.2

Corporate structure

Celera Corporation is part of a group headed by Quest Diagnostics. 31 entities, 9 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

  • Quest Diagnostics Secaucus, New Jersey, United States
    • Celera Corporation Alameda
    • Blueprint Genetics Oy Subsidiary · 100% · Espoo, Finland
    • QUEST DIAGNOSTICS INDIA PRIVATE LIMITED Subsidiary · 99.99% · Gurgaon, India
    • 100% AmeriPath Subsidiary · Florida, United States
    • 100% AmeriPath Hospital Services Subsidiary · Florida, United States
    • 100% AmeriPath Tucson, Inc. (AZ) AmeriPath Subsidiary · Arizona, United States
    • 100% Blueprint Genetics Oy Subsidiary · Finland
    • 100% Diagnostic Pathology Services, Inc. (OK) AmeriPath Subsidiary · Oklahoma, United States
    • 100% ExamOne Canada, Inc. Subsidiary · New Brunswick, Canada
    • 100% Haystactack Oncology GmbH Subsidiary · Germany
    • 100% Lab One of Subsidiary · Ohio, United States
    • 100% LifeLabs GP ULC Subsidiary · Ontario, Canada
    • 100% Quest Diagnostics (Shanghai) Co., Ltd. Subsidiary · China
    • 100% Quest Diagnostics do Brasil Ltda. Subsidiary · Brazil
    • 100% Quest Diagnostics Holdings Ltd. Subsidiary · United Kingdom
    • 100% Quest Diagnostics India Private Limited Subsidiary · India
    • 100% Quest Diagnostics International Holdings Limited Subsidiary · United Kingdom
    • 100% Quest Diagnostics Ireland Limited Subsidiary · Ireland
    • 100% Quest Diagnostics of Puerto Rico, Inc. Subsidiary · Puerto Rico, United States
    • 53.5% Associated Clinical Laboratories of Subsidiary · Pennsylvania, United States
    • AmeriPath Central Subsidiary · Florida, United States
    • AmeriPath North Subsidiary · Texas, United States
    • AmeriPath South Subsidiary · Florida, United States
    • Dermpath Diagnostics Subsidiary · Texas, United States
    • Institute, Inc. of Subsidiary · Virginia, United States
    • and 5 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.

The story

Founded by Craig Venter on May 1998.1

Originally headquartered in Rockville, Maryland (relocated to Alameda, California), it was established in May 1998 by PE Corporation (later renamed to Applera), with Dr. J. Craig Venter from The Institute for Genomic Research (TIGR) as its first president. While at TIGR, Venter and Hamilton Smith led the first successful effort to sequence an entire organism's genome, that of the Haemophilus influenzae bacterium. Celera was formed for the purpose of generating and commercializing genomic information. Its stock is a tracking stock of Applera, along with the tracking stock of Applera's larger Applied Biosystems Group business unit.

Celera sequenced the human genome at a fraction of the cost of the publicly funded Human Genome Project (HGP), using about $300 million of private funding versus approximately $3 billion of taxpayer dollars. However, a significant portion of the human genome had already been sequenced when Celera entered the field, and thus Celera did not incur any costs with obtaining the existing data, which was freely available to the public from GenBank. Celera's approach, which used shotgun sequencing, spurred the public HGP to accelerate its effort and shift its projected timetable from 2005 to 2003.

Critics of initial efforts by Celera Genomics to hold back data from sections of genome they sequenced for commercial exploitation felt that it would retard progress in science as a whole. These critics pointed to the open access policy for gene sequences from the publicly funded Human Genome Project. Later, the company changed their policy and made their sequences available for non-commercial use but set a maximum threshold for amount of sequence data that a researcher could download at any given time.

The rise and fall of Celera as an ambitious competitor of the Human Genome Project is the main subject of the book The Genome War by James Shreeve, who followed Venter around for two years in the process of writing the book. A view from the public effort's side is that of Nobel laureate Sir John Sulston in his book The Common Thread: A Story of Science, Politics, Ethics and the Human Genome. Anthropologist Paul Rabinow also based his 2005 book A Machine to Make a Future on Celera.

From Wikipedia’s article on Celera Corporation, shared under CC BY-SA 4.0.4

Leadership

Who has led Celera Corporation, and when. Pick a name to see everywhere that person has worked.

Subsidiaries and ownership

Parent company

From Wikidata.1

Timeline

  1. May 1998Founded Founded1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4